TriSalus Life Sciences, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $261.7M
- Price
- $4.25
- % Change (Daily % change from the live per-ticker quote feed.)
- -0.47%
- Volume
- 185.3K
About
TriSalus Life Sciences, Inc. is an immunotherapy firm dedicated to the research, development, and market introduction of treatments that leverage the body's immune system, primarily targeting liver and pancreatic cancers. The company's product portfolio includes the TriNav Infusion System, designed for hepatic arterial infusion to treat liver tumors, and the Pancreatic Retrograde Venous Infusion System, which addresses pancreatic tumors. Additionally, TriSalus is advancing SD-101, an investigational immunotherapeutic that incorporates pressure-enabled drug delivery technology. This experimental therapy is currently being explored for its application in hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company's operations are headquartered in Westminster, Colorado.
Quick stats
Shares outstanding61.6M
Computed float45.9M
Float / shares74.5%
Cash runway (months)13
Key info
SectorHealthcare
IndustryMedical - Devices
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001826667
Websitehttps://trisaluslifesci.com
AI Summary
AI-generated1/50
standardbullishfda approval
TriSalus Life Sciences Receives FDA Clearance for TriNav® Advance, Strengthening Comprehensive Pressure-Enabled Drug Delivery™ (PEDD™) Portfolio for Liver Embolization
TriSalus Life Sciences received FDA 510(k) clearance for TriNav Advance, the newest addition to its Pressure-Enabled Drug Delivery portfolio for liver embolization.
The new device adds access to small, distal vessels via a compatible microcatheter, and supports embolization procedures beyond the liver; a limited market release is planned over the coming weeks.
CEO Mary Szela said the clearance broadens the portfolio across the full range of liver embolization procedures and is expected to catalyze further physician adoption.